An experimental drug made by Bayer HealthCare extended the length of time that patients with gastrointestinal tumors survived without their disease getting worse, according to results of a late-stage clinical trial released Monday.
All men know: It’s not the fall that kills you; it’s that sudden stop at the end. Men smoke more, drink more and eat more. Men die sooner and are less likely to seek health care on their own. Men are full-throttle all-systems-go, until one day they’re not. Because it’s that sudden run-in with a heart attack or stroke, that sudden diagnosis of prostate or colon cancers, that slows them down.
Walgreens Specialty Pharmacy on Thursday added six medications to its oral oncology cycle management program, in a significant expansion of the comprehensive treatment and support program it provides to benefit patients, physicians and payers, the company announced.
Beauty company Coty and DKMS, the world's largest bone marrow donor center, jointly raised $3.2 million to support the fight against blood cancer during the recently held DKMS 6th Annual Gala: Linked Against Blood Cancer.
Breast cancer patients taking an experimental drug made by Roche subsidiary Genentech lived significantly longer than those taking another drug made by GlaxoSmithKline, according to results of a late-stage clinical trial.
Pills for treating cancer have created numerous alternatives to spending hours in a clinic or at home receiving chemotherapy infusions, but risks of drug interactions remain, according to a new survey by the research arm of pharmacy benefit manager Medco Health Solutions.
The FDA announced the approval of Genentech's Erivedge (vismodegib) for adults with basal cell carcinoma who are not surgery or radiation therapy candidates and whose disease is locally advanced or has spread to other parts of the body.
Diplomat Specialty Pharmacy has signed an agreement with a provider of acquisition and management services for oral cancer drugs that the companies said would allow for better access to the drugs and related programs.
A drug made by Amgen delayed the spread of prostate cancer to the bones in men with the disease and prolonged the survival of men with the condition, according to results of a late-stage clinical trial.